摘要
目的:评价复方玄驹胶囊联合前列舒通胶囊治疗ⅢB型前列腺炎患者的疗效和安全性。方法:100例ⅢB型前列腺炎患者分为观察组和对照组:50例为观察组,采用复方玄驹胶囊联合前列舒通胶囊治疗;50例为对照组,口服前列舒通胶囊治疗。结果:6周后随访时,观察组失访6例,对照组失访4例。两组患者治疗前入组时,一般情况比较差异无统计学意义(P>0.05),具有可比性。观察组总有效率为86.36%(38/44),高于对照组总有效率65.22%(30/46),差异具有统计学意义(P<0.01)。治疗6周后,观察组患者NIH-CPSI评分改善明显优于对照组,差异具有统计学意义(P<0.01)。治疗期间两组患者不良反应均轻微,无因此停药病例。结论:复方玄驹胶囊联合前列舒通胶囊治疗ⅢB型前列腺炎患者疗效可靠,副作用小,值得临床推广应用。
Objective： To evaluate the efficacy and safety of Fufangxuanju capsule combined with Qianlieshutong capsule treatment on the patients with type ⅢB prostatitis. Methods： 100 patients withtype ⅢB prostatitis were divided into observation group（ n = 50） and control group（ n = 50）. Observation group received treatment of Fufangxuanju capsule combined with Qianlieshutong capsule,while control group received Qianlieshutong capsule only. Results： In the 6-week follow-up survey,6 participants in observation group were lost,and 4 participants were lost in control group. The total effective rate of observation group was 86. 36%（ 38/44）,which was higher than that of control group（ 65. 22%,30/46）,with statistically significant difference（ P〈0. 01）. After treatment,NIH-CPSI of observation group was more significantly improved than that of control group（ P〈0. 01）. During the treatment,no obvious adverse reactions were observed among patients in the two groups. Conclusions： Treatment of Fufangxuanju capsule combined with Qianlieshutong capsule for patients with type ⅢB prostatitis is efficient and relatively safe,worthy of clinical application.
作者
肖飞
陈永华
谷现恩
XIAO Fei;CHEN Yonghua;GU Xianen(Department of Urology,Beijing Chuiy- angliu Hospital Affiliated to Tsinghua University,Beijing100022,China)
出处
《中国性科学》
2018年第5期13-15,共3页
Chinese Journal of Human Sexuality
基金
北京市朝阳区科技计划项目(CYSF162003)
